Licensing · Global (LMICs) · Announced 16 Nov 2026
Gilead Sciences → Eva Pharma
Gilead signed a royalty-free voluntary licence with Egypt's Eva Pharma to manufacture and supply investigational obeldesivir for Ebola Bundibugyo post-exposure prophylaxis across 127 mainly low- and lower-middle-income countries, pending trial data and approvals.
Parties: Gilead Sciences (United States) → Eva Pharma (Egypt)
- Deal type
- Licensing
- Value
- Royalty-free
- Territory
- 127 countries, primarily low- and lower-middle-income, including all African countries that have reported cases in the current Ebola Bundibugyo outbreak
- Therapeutic area
- Infectious Disease
- Asset
- obeldesivir
- Announced
- 16 Nov 2026
Our analysis
Why this matters
On 16 November 2026 Gilead Sciences announced royalty-free voluntary licensing agreements with three generic manufacturers — Eva Pharma, Dr. Reddy's Laboratories and Ferozsons Laboratories — for obeldesivir, an investigational oral antiviral being studied for post-exposure prophylaxis (PEP) of Ebola Bundibugyo virus disease (BVD). The licences cover 127 countries, primarily low- and lower-middle-income, including every African country that has reported cases in the current outbreak.
The agreements were signed before results are available from EBO-PEP, a partner-led Phase 3 randomised, placebo-controlled trial coordinated by ALIMA. Obeldesivir is not approved for any indication in any country; licensees may manufacture and supply it only if clinical data and regulatory authorisations support it. Technology-transfer discussions are underway, and Gilead says further manufacturers are under discussion.
The full analysis is free to read with a work email on this page.
Source: Gilead Sciences press release